All In Biotech

Drug Trial Radar · NCT03100825

A Long-term Safety Study of QVM149 in Japanese Patients With Asthma

A Multicenter, Open-label, Single Arm, 52-week Treatment Study to Assess the Safety of QVM149 in Japanese Patients With Asthma

Last checked: Nov 19, 2026Latest source record: Apr 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

96

Actual

Start

Apr 28, 2017

Primary completion

Sep 18, 2018

Study completion Apr 8, 2019

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 4, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to provide long term safety data of QVM149 in Japanese patients with asthma for the registration of QVM149 in Japan.

Conditions

  • Asthma

Interventions

  • QVM149Drug

    QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs)Time frame: Up to 52 Weeks

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Koga, Fukuoka, Japan

  • Novartis Investigative Site

    Yanagawa, Fukuoka, Japan

  • Novartis Investigative Site

    Maebashi, Gunma, Japan

  • Novartis Investigative Site

    Hiroshima, Hiroshima, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, Japan

  • Novartis Investigative Site

    Tomakomai, Hokkaido, Japan

  • Novartis Investigative Site

    Takamatsu, Kagawa-ken, Japan

  • Novartis Investigative Site

    Fujisawa, Kanagawa, Japan

  • Novartis Investigative Site

    Sagamihara, Kanagawa, Japan

  • Novartis Investigative Site

    Sagamihara, Kanagawa, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa, Japan

  • Novartis Investigative Site

    Yokkaichi, Mie-ken, Japan

  • Novartis Investigative Site

    Nagaoka, Niigata, Japan

  • Novartis Investigative Site

    Osaka, Osaka, Japan

  • Novartis Investigative Site

    Sakai, Osaka, Japan

  • Novartis Investigative Site

    Ageo, Saitama, Japan

  • Novartis Investigative Site

    Chuo Ku, Tokyo, Japan

  • Novartis Investigative Site

    Chuo-ku, Tokyo, Japan

  • Novartis Investigative Site

    Chuo-ku, Tokyo, Japan

  • Novartis Investigative Site

    Chuo-ku, Tokyo, Japan

  • Novartis Investigative Site

    Ōta-ku, Tokyo, Japan

  • Novartis Investigative Site

    Setagaya-ku, Tokyo, Japan

  • Novartis Investigative Site

    Setagaya-ku, Tokyo, Japan

  • Novartis Investigative Site

    Shinagawa-ku, Tokyo, Japan

  • Novartis Investigative Site

    Toshima Ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.